🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 81 (from laksa097)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa081.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://theedgemalaysia.com/node/764750\')), getAhrefsUnparsedNoserviceFromURL(\'https://theedgemalaysia.com/node/764750\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/theedgemalaysia.com\/node\/764750","crawl_time":1774370484,"first_indexed_time":1753942528,"http_code":200,"src_unparsed":"com,theedgemalaysia!\/node\/764750 s443","src_root_hash":"4868022189353796681","history_drop_reason":null,"meta_title":"Pharmaniaga completes rights issue, private placement exercises; on track to exit PN17 by 1Q2026","meta_descriptions":["KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:PHARMA) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026."],"attrs_boilerpipe_text":"KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:\nPHARMA\n) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026.\nWith the fundraising exercises now completed, the group will proceed to the final phase of its regularisation plan — a capital reduction exercise slated for completion by mid-August 2025, Pharmaniaga said in a statement.\nThe pharmaceutical group said its renounceable rights issue involving 3.46 billion shares was fully subscribed, with an oversubscription rate of 26.14% from existing shareholders.\nConcurrently, the group’s private placement exercise raised RM223.7 million from the issuance of 1.66 billion shares, attracting participation from 19 new investors.\nDespite this new equity injection, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd remain the group’s major shareholders with a combined stake of 43.9%, holding 8.7% and 35.2% respectively.\n“We are encouraged by the solid support from our shareholders and new investors. The oversubscription of our rights issue reflects deep market recognition of our business fundamentals, recovery plan and leadership,” said Pharmaniaga managing director Datuk Zulkifli Jafar. \nHe added that the participation of institutional and reputable investors in the private placement is a strong endorsement of Pharmaniaga’s broader objective to support Malaysia’s healthcare resilience and pharmaceutical self-sufficiency.\nZulkifli said the strengthened balance sheet will allow the group to reduce borrowings and scale up operations, particularly in high-impact areas such as the development of human insulin, vaccines, and generic drugs.\nPharmaniaga is currently advancing the establishment of Malaysia’s first locally owned insulin and vaccine production facilities.\n“All hands are on deck, as we intensify our biopharmaceutical manufacturing initiatives, fortify our logistics and distribution with new warehouse developments, and sustain strong momentum in our Indonesia operations,” he added. \nAt Thursday’s noon break, shares of Pharmaniaga rose 6.25% or one sen at 17 sen, giving it a market capitalisation of RM833.03 million. The counter has fallen over 51% year-to-date. ","attrs_markdown":"[Subscribe to The Edge Malaysia packages](https:\/\/theedgemalaysia.com\/subscription)\n\n[Register to Newsletter](https:\/\/theedgemalaysia.com\/newsletter)\n\nTuesday 24 Mar 2026\n\n[Home](https:\/\/theedgemalaysia.com\/)\n\n[Corporate](https:\/\/theedgemalaysia.com\/categories\/corporate)\n\n[Economy](https:\/\/theedgemalaysia.com\/categories\/economy)\n\n[Court & Politics](https:\/\/theedgemalaysia.com\/)\n\n[Sections](https:\/\/theedgemalaysia.com\/)\n\n[EdgeTV](https:\/\/theedgemalaysia.com\/)\n\n[Tech](https:\/\/theedgemalaysia.com\/categories\/technology)\n\n[Opinion](https:\/\/theedgemalaysia.com\/)\n\n[新闻](https:\/\/theedgemalaysia.com\/categories\/news)\n\n[Home](https:\/\/theedgemalaysia.com\/)\n\n[Corporate](https:\/\/theedgemalaysia.com\/categories\/corporate)\n\n[Economy](https:\/\/theedgemalaysia.com\/categories\/economy)\n\n[Court & Politics](https:\/\/theedgemalaysia.com\/)\n\n[Sections](https:\/\/theedgemalaysia.com\/)\n\n[EdgeTV](https:\/\/theedgemalaysia.com\/)\n\n[Tech](https:\/\/theedgemalaysia.com\/categories\/technology)\n\n[Opinion](https:\/\/theedgemalaysia.com\/)\n\n[新闻](https:\/\/theedgemalaysia.com\/categories\/news)\n\n[Home](https:\/\/theedgemalaysia.com\/)\n\n[Corporate](https:\/\/theedgemalaysia.com\/categories\/corporate)\n\n[Economy](https:\/\/theedgemalaysia.com\/categories\/economy)\n\n[Court & Politics](https:\/\/theedgemalaysia.com\/)\n\n[Sections](https:\/\/theedgemalaysia.com\/)\n\n[EdgeTV](https:\/\/theedgemalaysia.com\/)\n\n[Tech](https:\/\/theedgemalaysia.com\/categories\/technology)\n\n[Opinion](https:\/\/theedgemalaysia.com\/)\n\n[新闻](https:\/\/theedgemalaysia.com\/categories\/news)\n\n[![](https:\/\/myassets.theedgemalaysia.com\/img\/Askedge.svg)](https:\/\/theedgemalaysia.com\/askedge\/)\n\nBURSA\n\nSGX\n\n1. [Home](https:\/\/theedgemalaysia.com\/)\n2. Pharmaniaga completes rights issue, private placement exercises; on track to exit PN17 by 1Q2026\n\n[Corporate](https:\/\/theedgemalaysia.com\/categories\/Corporate)\n\n[Malaysia](https:\/\/theedgemalaysia.com\/categories\/Malaysia)\n\nPharmaniaga completes rights issue, private placement exercises; on track to exit PN17 by 1Q2026\n\nBy [Syafiqah Salim](https:\/\/theedgemalaysia.com\/author\/Syafiqah%20Salim?page=1) \/ [theedgemalaysia.com](https:\/\/theedgemalaysia.com\/source\/theedgemalaysia.com?page=1)\n\n31 Jul 2025, 02:12 pm\n\n![main news image](https:\/\/theedgemalaysia.com\/_next\/image?url=%2Fimages%2Fdefault_theedgemarkets.jpeg&w=1920&q=75)\n\nKUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:[PHARMA](https:\/\/theedgemalaysia.com\/askedge\/klse\/7081)) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026.\n\nWith the fundraising exercises now completed, the group will proceed to the final phase of its regularisation plan — a capital reduction exercise slated for completion by mid-August 2025, Pharmaniaga said in a statement.\n\nThe pharmaceutical group said its renounceable rights issue involving 3.46 billion shares was fully subscribed, with an oversubscription rate of 26.14% from existing shareholders.\n\nConcurrently, the group’s private placement exercise raised RM223.7 million from the issuance of 1.66 billion shares, attracting participation from 19 new investors.\n\nDespite this new equity injection, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd remain the group’s major shareholders with a combined stake of 43.9%, holding 8.7% and 35.2% respectively.\n\n“We are encouraged by the solid support from our shareholders and new investors. The oversubscription of our rights issue reflects deep market recognition of our business fundamentals, recovery plan and leadership,” said Pharmaniaga managing director Datuk Zulkifli Jafar.\n\nHe added that the participation of institutional and reputable investors in the private placement is a strong endorsement of Pharmaniaga’s broader objective to support Malaysia’s healthcare resilience and pharmaceutical self-sufficiency.\n\nZulkifli said the strengthened balance sheet will allow the group to reduce borrowings and scale up operations, particularly in high-impact areas such as the development of human insulin, vaccines, and generic drugs.\n\nPharmaniaga is currently advancing the establishment of Malaysia’s first locally owned insulin and vaccine production facilities.\n\n“All hands are on deck, as we intensify our biopharmaceutical manufacturing initiatives, fortify our logistics and distribution with new warehouse developments, and sustain strong momentum in our Indonesia operations,” he added.\n\nAt Thursday’s noon break, shares of Pharmaniaga rose 6.25% or one sen at 17 sen, giving it a market capitalisation of RM833.03 million. The counter has fallen over 51% year-to-date.\n\nEdited ByIsabelle Francis\n\n- Most Read\n- Just In\n\nLevel 3, Menara KLK, 1 Jalan PJU 7\/6, Mutiara Damansara, 47810 Petaling Jaya, Selangor, Malaysia\n\n[(+603) 7721 8000](<tel: (+603) 7721 8000>)\n\n[info@bizedge.com](<mailto: info@bizedge.com>)\n\n- [Home](https:\/\/theedgemalaysia.com\/)\n- [Contact us](https:\/\/theedgemalaysia.com\/contact-us)\n- [Sitemap](https:\/\/theedgemalaysia.com\/site-map)\n- [About us](https:\/\/theedgemalaysia.com\/about-us)\n- [Advertise with us](https:\/\/theedgemalaysia.com\/advertise-with-us)\n- [Terms & Conditions](https:\/\/theedgemalaysia.com\/terms-of-use)\n- [Join us](https:\/\/theedgemalaysia.com\/join-us)\n- [Subscription](https:\/\/theedgemalaysia.com\/subscription)\n- [PDPA](https:\/\/theedgemalaysia.com\/pdpa)\n- [Newsletter](https:\/\/theedgemalaysia.com\/newsletter)\n- [Digital Editions](https:\/\/digital.theedgemalaysia.com\/theedgemediagroup\/newsstand\/title\/tem)\n\nCopyright © 1999-2026 The Edge Communications Sdn. Bhd. 199301012242 (266980-X). All rights reserved\n\n![share icon](https:\/\/theedgemalaysia.com\/_next\/static\/media\/print.78b9b218.svg)\n\nPrint\n\n![share icon](https:\/\/theedgemalaysia.com\/_next\/static\/media\/font.0ac2362a.svg)\n\nText Size\n\n![share icon](https:\/\/theedgemalaysia.com\/_next\/static\/media\/share.e447046e.svg)\n\nShare\n\n![](https:\/\/www.facebook.com\/tr?id=919789282657588&ev=PageView&noscript=1)","attrs_readable_markdown":"KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:[PHARMA](https:\/\/theedgemalaysia.com\/askedge\/klse\/7081)) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026.\n\nWith the fundraising exercises now completed, the group will proceed to the final phase of its regularisation plan — a capital reduction exercise slated for completion by mid-August 2025, Pharmaniaga said in a statement.\n\nThe pharmaceutical group said its renounceable rights issue involving 3.46 billion shares was fully subscribed, with an oversubscription rate of 26.14% from existing shareholders.\n\nConcurrently, the group’s private placement exercise raised RM223.7 million from the issuance of 1.66 billion shares, attracting participation from 19 new investors.\n\nDespite this new equity injection, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd remain the group’s major shareholders with a combined stake of 43.9%, holding 8.7% and 35.2% respectively.\n\n“We are encouraged by the solid support from our shareholders and new investors. The oversubscription of our rights issue reflects deep market recognition of our business fundamentals, recovery plan and leadership,” said Pharmaniaga managing director Datuk Zulkifli Jafar.\n\nHe added that the participation of institutional and reputable investors in the private placement is a strong endorsement of Pharmaniaga’s broader objective to support Malaysia’s healthcare resilience and pharmaceutical self-sufficiency.\n\nZulkifli said the strengthened balance sheet will allow the group to reduce borrowings and scale up operations, particularly in high-impact areas such as the development of human insulin, vaccines, and generic drugs.\n\nPharmaniaga is currently advancing the establishment of Malaysia’s first locally owned insulin and vaccine production facilities.\n\n“All hands are on deck, as we intensify our biopharmaceutical manufacturing initiatives, fortify our logistics and distribution with new warehouse developments, and sustain strong momentum in our Indonesia operations,” he added.\n\nAt Thursday’s noon break, shares of Pharmaniaga rose 6.25% or one sen at 17 sen, giving it a market capitalisation of RM833.03 million. The counter has fallen over 51% year-to-date.","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

14 days ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.5 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://theedgemalaysia.com/node/764750
Last Crawled	2026-03-24 16:41:24 (14 days ago)
First Indexed	2025-07-31 06:15:28 (8 months ago)
HTTP Status Code	200
Meta Title	Pharmaniaga completes rights issue, private placement exercises; on track to exit PN17 by 1Q2026
Meta Description	KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:PHARMA) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026.
Meta Canonical	null
Boilerpipe Text	KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL: PHARMA ) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026. With the fundraising exercises now completed, the group will proceed to the final phase of its regularisation plan — a capital reduction exercise slated for completion by mid-August 2025, Pharmaniaga said in a statement. The pharmaceutical group said its renounceable rights issue involving 3.46 billion shares was fully subscribed, with an oversubscription rate of 26.14% from existing shareholders. Concurrently, the group’s private placement exercise raised RM223.7 million from the issuance of 1.66 billion shares, attracting participation from 19 new investors. Despite this new equity injection, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd remain the group’s major shareholders with a combined stake of 43.9%, holding 8.7% and 35.2% respectively. “We are encouraged by the solid support from our shareholders and new investors. The oversubscription of our rights issue reflects deep market recognition of our business fundamentals, recovery plan and leadership,” said Pharmaniaga managing director Datuk Zulkifli Jafar. He added that the participation of institutional and reputable investors in the private placement is a strong endorsement of Pharmaniaga’s broader objective to support Malaysia’s healthcare resilience and pharmaceutical self-sufficiency. Zulkifli said the strengthened balance sheet will allow the group to reduce borrowings and scale up operations, particularly in high-impact areas such as the development of human insulin, vaccines, and generic drugs. Pharmaniaga is currently advancing the establishment of Malaysia’s first locally owned insulin and vaccine production facilities. “All hands are on deck, as we intensify our biopharmaceutical manufacturing initiatives, fortify our logistics and distribution with new warehouse developments, and sustain strong momentum in our Indonesia operations,” he added. At Thursday’s noon break, shares of Pharmaniaga rose 6.25% or one sen at 17 sen, giving it a market capitalisation of RM833.03 million. The counter has fallen over 51% year-to-date.
Markdown	[Subscribe to The Edge Malaysia packages](https://theedgemalaysia.com/subscription) [Register to Newsletter](https://theedgemalaysia.com/newsletter) Tuesday 24 Mar 2026 [Home](https://theedgemalaysia.com/) [Corporate](https://theedgemalaysia.com/categories/corporate) [Economy](https://theedgemalaysia.com/categories/economy) [Court & Politics](https://theedgemalaysia.com/) [Sections](https://theedgemalaysia.com/) [EdgeTV](https://theedgemalaysia.com/) [Tech](https://theedgemalaysia.com/categories/technology) [Opinion](https://theedgemalaysia.com/) [新闻](https://theedgemalaysia.com/categories/news) [Home](https://theedgemalaysia.com/) [Corporate](https://theedgemalaysia.com/categories/corporate) [Economy](https://theedgemalaysia.com/categories/economy) [Court & Politics](https://theedgemalaysia.com/) [Sections](https://theedgemalaysia.com/) [EdgeTV](https://theedgemalaysia.com/) [Tech](https://theedgemalaysia.com/categories/technology) [Opinion](https://theedgemalaysia.com/) [新闻](https://theedgemalaysia.com/categories/news) [Home](https://theedgemalaysia.com/) [Corporate](https://theedgemalaysia.com/categories/corporate) [Economy](https://theedgemalaysia.com/categories/economy) [Court & Politics](https://theedgemalaysia.com/) [Sections](https://theedgemalaysia.com/) [EdgeTV](https://theedgemalaysia.com/) [Tech](https://theedgemalaysia.com/categories/technology) [Opinion](https://theedgemalaysia.com/) [新闻](https://theedgemalaysia.com/categories/news) [![](https://myassets.theedgemalaysia.com/img/Askedge.svg)](https://theedgemalaysia.com/askedge/) BURSA SGX 1. [Home](https://theedgemalaysia.com/) 2. Pharmaniaga completes rights issue, private placement exercises; on track to exit PN17 by 1Q2026 [Corporate](https://theedgemalaysia.com/categories/Corporate) [Malaysia](https://theedgemalaysia.com/categories/Malaysia) Pharmaniaga completes rights issue, private placement exercises; on track to exit PN17 by 1Q2026 By [Syafiqah Salim](https://theedgemalaysia.com/author/Syafiqah%20Salim?page=1) / [theedgemalaysia.com](https://theedgemalaysia.com/source/theedgemalaysia.com?page=1) 31 Jul 2025, 02:12 pm ![main news image](https://theedgemalaysia.com/_next/image?url=%2Fimages%2Fdefault_theedgemarkets.jpeg&w=1920&q=75) KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:[PHARMA](https://theedgemalaysia.com/askedge/klse/7081)) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026. With the fundraising exercises now completed, the group will proceed to the final phase of its regularisation plan — a capital reduction exercise slated for completion by mid-August 2025, Pharmaniaga said in a statement. The pharmaceutical group said its renounceable rights issue involving 3.46 billion shares was fully subscribed, with an oversubscription rate of 26.14% from existing shareholders. Concurrently, the group’s private placement exercise raised RM223.7 million from the issuance of 1.66 billion shares, attracting participation from 19 new investors. Despite this new equity injection, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd remain the group’s major shareholders with a combined stake of 43.9%, holding 8.7% and 35.2% respectively. “We are encouraged by the solid support from our shareholders and new investors. The oversubscription of our rights issue reflects deep market recognition of our business fundamentals, recovery plan and leadership,” said Pharmaniaga managing director Datuk Zulkifli Jafar. He added that the participation of institutional and reputable investors in the private placement is a strong endorsement of Pharmaniaga’s broader objective to support Malaysia’s healthcare resilience and pharmaceutical self-sufficiency. Zulkifli said the strengthened balance sheet will allow the group to reduce borrowings and scale up operations, particularly in high-impact areas such as the development of human insulin, vaccines, and generic drugs. Pharmaniaga is currently advancing the establishment of Malaysia’s first locally owned insulin and vaccine production facilities. “All hands are on deck, as we intensify our biopharmaceutical manufacturing initiatives, fortify our logistics and distribution with new warehouse developments, and sustain strong momentum in our Indonesia operations,” he added. At Thursday’s noon break, shares of Pharmaniaga rose 6.25% or one sen at 17 sen, giving it a market capitalisation of RM833.03 million. The counter has fallen over 51% year-to-date. Edited ByIsabelle Francis - Most Read - Just In Level 3, Menara KLK, 1 Jalan PJU 7/6, Mutiara Damansara, 47810 Petaling Jaya, Selangor, Malaysia [(+603) 7721 8000](<tel: (+603) 7721 8000>) [info@bizedge.com](<mailto: info@bizedge.com>) - [Home](https://theedgemalaysia.com/) - [Contact us](https://theedgemalaysia.com/contact-us) - [Sitemap](https://theedgemalaysia.com/site-map) - [About us](https://theedgemalaysia.com/about-us) - [Advertise with us](https://theedgemalaysia.com/advertise-with-us) - [Terms & Conditions](https://theedgemalaysia.com/terms-of-use) - [Join us](https://theedgemalaysia.com/join-us) - [Subscription](https://theedgemalaysia.com/subscription) - [PDPA](https://theedgemalaysia.com/pdpa) - [Newsletter](https://theedgemalaysia.com/newsletter) - [Digital Editions](https://digital.theedgemalaysia.com/theedgemediagroup/newsstand/title/tem) Copyright © 1999-2026 The Edge Communications Sdn. Bhd. 199301012242 (266980-X). All rights reserved ![share icon](https://theedgemalaysia.com/_next/static/media/print.78b9b218.svg) Print ![share icon](https://theedgemalaysia.com/_next/static/media/font.0ac2362a.svg) Text Size ![share icon](https://theedgemalaysia.com/_next/static/media/share.e447046e.svg) Share ![](https://www.facebook.com/tr?id=919789282657588&ev=PageView&noscript=1)
Readable Markdown	KUALA LUMPUR (July 31): Pharmaniaga Bhd (KL:[PHARMA](https://theedgemalaysia.com/askedge/klse/7081)) has completed two components of its regularisation plan — a rights issue and a private placement — paving the way for the group to exit its Practice Note 17 (PN17) status by the first quarter of 2026. With the fundraising exercises now completed, the group will proceed to the final phase of its regularisation plan — a capital reduction exercise slated for completion by mid-August 2025, Pharmaniaga said in a statement. The pharmaceutical group said its renounceable rights issue involving 3.46 billion shares was fully subscribed, with an oversubscription rate of 26.14% from existing shareholders. Concurrently, the group’s private placement exercise raised RM223.7 million from the issuance of 1.66 billion shares, attracting participation from 19 new investors. Despite this new equity injection, Lembaga Tabung Angkatan Tentera (LTAT) and Boustead Holdings Bhd remain the group’s major shareholders with a combined stake of 43.9%, holding 8.7% and 35.2% respectively. “We are encouraged by the solid support from our shareholders and new investors. The oversubscription of our rights issue reflects deep market recognition of our business fundamentals, recovery plan and leadership,” said Pharmaniaga managing director Datuk Zulkifli Jafar. He added that the participation of institutional and reputable investors in the private placement is a strong endorsement of Pharmaniaga’s broader objective to support Malaysia’s healthcare resilience and pharmaceutical self-sufficiency. Zulkifli said the strengthened balance sheet will allow the group to reduce borrowings and scale up operations, particularly in high-impact areas such as the development of human insulin, vaccines, and generic drugs. Pharmaniaga is currently advancing the establishment of Malaysia’s first locally owned insulin and vaccine production facilities. “All hands are on deck, as we intensify our biopharmaceutical manufacturing initiatives, fortify our logistics and distribution with new warehouse developments, and sustain strong momentum in our Indonesia operations,” he added. At Thursday’s noon break, shares of Pharmaniaga rose 6.25% or one sen at 17 sen, giving it a market capitalisation of RM833.03 million. The counter has fallen over 51% year-to-date.
Shard	81 (laksa)
Root Hash	4868022189353796681
Unparsed URL	com,theedgemalaysia!/node/764750 s443